XML 56 R41.htm IDEA: XBRL DOCUMENT v3.25.2
Accrued Expenses and Other Current Liabilities (Tables)
 12 Months Ended
Dec. 31, 2024
Accrued Liabilities and Other Liabilities [Abstract]  
Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

 

 

December 31,

 

 

2024

 

 

2023

 

Marketing reimbursement

 

$

821

 

 

$

2,834

 

Accrued compensation

 

 

1,046

 

 

 

1,687

 

Accrued clinical trials and R&D

 

 

—

 

 

 

3,694

 

Accrued selling and marketing

 

 

91

 

 

 

1,110

 

Accrued professional fees

 

 

1,164

 

 

 

1,505

 

Accrued warranty

 

 

14

 

 

 

44

 

Accrued restructuring

 

 

3,165

 

 

 

655

 

Other accrued expenses

 

 

5,121

 

 

 

3,966

 

Total accrued expenses and other current liabilities

 

$

11,422

 

 

$

15,495

 
Schedule of Activity in Restructuring Accrual The following table rolls forward the activity in the restructuring accrual for the December 2023 action for the year ended December 31, 2024:

 

Accrual at December 31, 2023

 

$

655

 

Additional restructuring and related costs

 

 

19

 

Cash payments

 

 

(674

)

Accrual at December 31, 2024

 

$

—

 
The following table rolls forward the activity in the restructuring accrual for the November 2024 action for the year ended December 31, 2024:

 

Accrual at December 31, 2023

 

$

—

 

Restructuring charges and related costs

 

 

3,953

 

Cash payments

 

 

(788

)

Accrual at December 31, 2024

 

$

3,165